Release Date: 30/08/16 08:25 Summary: Appendix 4E & Annual Report to shareholders-AYG.AX Price Sensitive: Yes Download Document 456.75KB Download
NTI Neurotech knocked back by FDA as agency declares target condition not rare enough for special status